Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

17 Jul 2013 07:00

RNS Number : 4730J
Imperial Innovations Group plc
17 July 2013
 



17 July 2013

 

Imperial Innovations Group plc

 

Board change

 

Imperial Innovations Group plc (AIM: IVO, "Innovations" or "the Group"), a leading technology commercialisation and investment group, announces that Susan Searle has stepped down as Chief Executive Officer. Russ Cummings, Chief Investment Officer and a director since the Group's flotation in 2006, has become Chief Executive Officer with immediate effect.

 

Russ Cummings previously worked at Scottish Equity Partners where as director in the Information Technology Group he was responsible for investment in high growth technology companies. Previously, Russ worked at 3i Group for 16 years including being a director in their UK Technology Group and at Rolls-Royce Motors as a development engineer. Russ has a BSc in Mechanical Engineering from Imperial College London.

 

Martin Knight, Chairman of the Group, said:

 

"On behalf of the Board and the Group as whole, I would like to thank Susan for her considerable contribution over the last nearly 20 years, 11 of which have been as Chief Executive Officer. She led our Admission to AIM in 2006 and two subsequent equity fund raisings.

 

"During her tenure, she transformed the Group from an operational division of Imperial College London, as its technology transfer office, to a major independent venture capital and technology licensing business.

 

"Thanks to her efforts, Innovations now has a stable platform from which it can deliver its long-term ventures and licensing business objectives. We all wish her well for the future.

 

"Russ has an excellent track record in early stage investing and high growth companies spanning both the healthcare and technology sectors. He was recruited in 2006 as CIO to build the investment team. He has played a significant role on the boards of two of our flagship investments, Nexeon and Circassia.

 

"Russ has been a key part of the management team and is ideally suited to lead Innovations in the next phase of its development."

 

Susan Searle said:

 

"I feel privileged for over 11 years to have led the management team at Innovations in building such a great company that it is today. But I have decided that now is the right time for me to step down. The timing of this decision is both good for me and for the business and enables my successor to make a very smooth transition to his role.

 

"The business is currently in a strong position and has recently concluded an additional £30m of funding from the European Investment Bank, enabling the Group to grow its investments still further. Innovations has some very exciting companies in its portfolio which we have worked hard to support and are based on world class science, with high quality management and are backed by strong investment syndicates.

 

"The Innovations story is set to continue and thrive in the long term and I wish it and the team every success.

 

"I now plan to go plural and to join a number of both larger and smaller public and private companies across a range of sectors, including biotech, engineering and technology, and investment in the UK and internationally."

 

Enquiries:

 

Imperial Innovations Group Plc

020 7594 6506

Martin Knight, Chairman

College Hill

020 7457 2020

Adrian Duffield/Tim Watson/Rozi Morris

J.P. Morgan Cazenove

020 7742 4000

Michael Wentworth Stanley/Alec Pratt

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGGUCCMUPWGQQ
Date   Source Headline
7th Jun 20177:00 amRNSForm 8 (OPD) IP Group PLC
6th Jun 201711:19 amRNSForm 8.3 - Touchstone Innovations
5th Jun 201712:46 pmRNSForm 8.3 - Touchstone Innovations Plc
1st Jun 20172:41 pmBUSForm 8.3 - Touchstone Innovations plc
1st Jun 20177:00 amRNSChairman's letter to shareholders
31st May 20175:58 pmRNSForm 8.5 (EPT/RI) - Touchstone Innovations Plc
31st May 201712:01 pmRNSForm 8.3 - Touchstone Innovations Plc
30th May 20177:00 amRNSForm 8.3 - Touchstone Innovations Plc
26th May 201712:29 pmRNSForm 8.3 - Touchstone Innovations Plc
25th May 201712:15 pmRNSForm 8.3 - Touchstone Innovations Plc
25th May 201712:14 pmRNSForm 8.3 - Touchstone Innovations Plc
25th May 201712:10 pmRNSForm 8.3 - IP Group Plc
24th May 20172:55 pmRNSForm 8.3 - IP Group plc
24th May 20172:52 pmRNSForm 8.3 - Touchstone Innovations plc
24th May 20172:51 pmRNSForm 8.3 - IP Group Plc
24th May 20172:41 pmRNSForm 8.3 - Touchstone Innovations Plc
24th May 20171:15 pmRNSForm 8.3 - Touchstone Innovations Plc
24th May 201711:17 amBUSForm 8 (DD) - Touchstone Innovations Plc.
23rd May 201712:05 pmRNSUpdate on possible offer
23rd May 201711:45 amRNSForm 8.3 - Touchstone Innovations Plc
23rd May 201710:33 amRNSStatement re Possible Offer
23rd May 20177:01 amRNSStatement re Possible Offer
21st Apr 201711:21 amRNSInnovations invests £2.9m in Abzena placing
6th Apr 20177:00 amRNSInnovations provides seed funding for Cardian
31st Mar 20177:00 amRNSHalf Yearly Report
20th Mar 20177:05 amRNSInnovations supports funding round in Pulmocide
16th Mar 20177:00 amRNSInnovations invests in Cell Medica funding round
14th Mar 20177:00 amRNSInnovations supports funding round in Resolver
6th Mar 20177:00 amRNSInnovations leads £12m funding round in Garrison
28th Feb 201711:11 amRNSNotice of Results
21st Feb 20177:03 amRNSCell Medica granted FDA Fast Track designation
26th Jan 20172:00 pmRNSDirectorate Change
5th Jan 20177:00 amRNSChange of name to Touchstone Innovations plc
4th Jan 20179:00 amRNSAppointment of Joint Broker
20th Dec 201612:03 pmRNSPsiOxus signs exclusive licence agreement with BMS
28th Nov 20167:02 amRNSPortfolio company TopiVert receives IND approval
23rd Nov 20165:56 pmRNSGrant of share options
21st Nov 201612:53 pmRNSResult of AGM
28th Oct 201612:30 pmRNSProposed change of name to Touchstone Innovations
28th Oct 201612:29 pmRNSPosting of Annual Report and Notice of AGM
24th Oct 20167:12 amRNSVeryan announces completion of subject enrolment
13th Oct 20167:00 amRNSFinal Results
10th Oct 20161:02 pmRNSCrescendo Biologics sign collaboration with Takeda
6th Oct 20167:02 amRNSFirst patients dosed in TopiVert's Phase IIa study
3rd Oct 201612:10 pmRNSSale of Innovations portfolio company Permasense
21st Sep 20167:06 amRNSInnovations invests £5.1m in Artios Pharma Limited
14th Sep 201612:02 pmRNSNotice of Results
13th Sep 20164:08 pmRNSTR-1: Notification of major interest in shares
9th Sep 20161:15 pmRNSHolding(s) in Company
6th Sep 20164:17 pmRNSEdison issues update on Imperial Innovations (IVO)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.